Parexel has announced it will open a new clinical trial supplies depot in China to support timely access to supplies and medications to clinical sites and patients. China continues to be a major growth market for clinical trials and for Parexel.
The China Depot is the latest addition to Parexel’s network of three Depot locations and three Coordination Hub and Distribution Centers globally. These locations are supported by 360+ colleagues in Parexel’s Clinical Trial Supplies & Logistics (CTS&L) team who have supported more than 110,000 patients across more than 500 active studies over the last 12 months.
Located in the Suzhou New District ESR Campus, the China Depot will be equipped with temperature storage (ambient, 2-8C, -20C) and secondary packaging and labeling capabilities. Parexel is making a $3 million investment in the new depot location and expects construction to be completed in November 2021 with the site fully operational by mid-2022.
Moving forward, the Pan-Asia distribution strategy for clinical supplies will be driven by the China Depot and Parexel’s Singapore Coordination Hub and Distribution Center. The new location provides critical clinical trial supplies, ancillary supplies and laboratory logistics services in the Asia/Pacific region for Parexel.
For more information, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.